168 related articles for article (PubMed ID: 20444960)
1. Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function.
Yin L; Ahmad R; Kosugi M; Kufe T; Vasir B; Avigan D; Kharbanda S; Kufe D
Mol Pharmacol; 2010 Aug; 78(2):166-74. PubMed ID: 20444960
[TBL] [Abstract][Full Text] [Related]
2. MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells.
Kawano T; Ahmad R; Nogi H; Agata N; Anderson K; Kufe D
Int J Oncol; 2008 Jul; 33(1):153-9. PubMed ID: 18575761
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH.
Yin L; Kosugi M; Kufe D
Blood; 2012 Jan; 119(3):810-6. PubMed ID: 22117045
[TBL] [Abstract][Full Text] [Related]
4. Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells.
Alam M; Rajabi H; Ahmad R; Jin C; Kufe D
Oncotarget; 2014 May; 5(9):2622-34. PubMed ID: 24770886
[TBL] [Abstract][Full Text] [Related]
5. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor.
Ahmad R; Raina D; Joshi MD; Kawano T; Ren J; Kharbanda S; Kufe D
Cancer Res; 2009 Sep; 69(17):7013-21. PubMed ID: 19706766
[TBL] [Abstract][Full Text] [Related]
6. MUC1-C is a target in lenalidomide resistant multiple myeloma.
Yin L; Tagde A; Gali R; Tai YT; Hideshima T; Anderson K; Avigan D; Kufe D
Br J Haematol; 2017 Sep; 178(6):914-926. PubMed ID: 28643330
[TBL] [Abstract][Full Text] [Related]
7. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.
Raina D; Kosugi M; Ahmad R; Panchamoorthy G; Rajabi H; Alam M; Shimamura T; Shapiro GI; Supko J; Kharbanda S; Kufe D
Mol Cancer Ther; 2011 May; 10(5):806-16. PubMed ID: 21421804
[TBL] [Abstract][Full Text] [Related]
8. MUC1 oncoprotein is a druggable target in human prostate cancer cells.
Joshi MD; Ahmad R; Yin L; Raina D; Rajabi H; Bubley G; Kharbanda S; Kufe D
Mol Cancer Ther; 2009 Nov; 8(11):3056-65. PubMed ID: 19887552
[TBL] [Abstract][Full Text] [Related]
9. MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells.
Yin L; Wu Z; Avigan D; Rosenblatt J; Stone R; Kharbanda S; Kufe D
Blood; 2011 May; 117(18):4863-70. PubMed ID: 21422470
[TBL] [Abstract][Full Text] [Related]
10. MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling.
Ahmad R; Raina D; Trivedi V; Ren J; Rajabi H; Kharbanda S; Kufe D
Nat Cell Biol; 2007 Dec; 9(12):1419-27. PubMed ID: 18037881
[TBL] [Abstract][Full Text] [Related]
11. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma.
Uematsu A; Kido K; Manabe E; Takeda H; Takahashi H; Hayashi M; Imai Y; Sawasaki T
Biochem Biophys Res Commun; 2018 Jan; 495(3):2289-2295. PubMed ID: 29284118
[TBL] [Abstract][Full Text] [Related]
12. MUC1-C activates the TAK1 inflammatory pathway in colon cancer.
Takahashi H; Jin C; Rajabi H; Pitroda S; Alam M; Ahmad R; Raina D; Hasegawa M; Suzuki Y; Tagde A; Bronson RT; Weichselbaum R; Kufe D
Oncogene; 2015 Oct; 34(40):5187-97. PubMed ID: 25659581
[TBL] [Abstract][Full Text] [Related]
13. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
[TBL] [Abstract][Full Text] [Related]
14. Importin β1 mediates nuclear factor-κB signal transduction into the nuclei of myeloma cells and affects their proliferation and apoptosis.
Yan W; Li R; He J; Du J; Hou J
Cell Signal; 2015 Apr; 27(4):851-9. PubMed ID: 25643631
[TBL] [Abstract][Full Text] [Related]
15. MUC1/KL-6 expression confers an aggressive phenotype upon myeloma cells.
Endo S; Nishimura N; Kawano Y; Ueno N; Ueno S; Tatetsu H; Komohara Y; Takeya M; Hata H; Mitsuya H; Masao M; Okuno Y
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):246-252. PubMed ID: 30420285
[TBL] [Abstract][Full Text] [Related]
16. DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7.
Li Y; Chen W; Ren J; Yu WH; Li Q; Yoshida K; Kufe D
Cancer Biol Ther; 2003; 2(2):187-93. PubMed ID: 12750561
[TBL] [Abstract][Full Text] [Related]
17. MUC1 protein induces urokinase-type plasminogen activator (uPA) by forming a complex with NF-κB p65 transcription factor and binding to the uPA promoter, leading to enhanced invasiveness of cancer cells.
Mori Y; Akita K; Tanida S; Ishida A; Toda M; Inoue M; Yashiro M; Sawada T; Hirakawa K; Nakada H
J Biol Chem; 2014 Dec; 289(51):35193-204. PubMed ID: 25371209
[TBL] [Abstract][Full Text] [Related]
18. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis.
Chen H; Li M; Campbell RA; Burkhardt K; Zhu D; Li SG; Lee HJ; Wang C; Zeng Z; Gordon MS; Bonavida B; Berenson JR
Oncogene; 2006 Oct; 25(49):6520-7. PubMed ID: 16702955
[TBL] [Abstract][Full Text] [Related]
19. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells.
Raina D; Ahmad R; Joshi MD; Yin L; Wu Z; Kawano T; Vasir B; Avigan D; Kharbanda S; Kufe D
Cancer Res; 2009 Jun; 69(12):5133-41. PubMed ID: 19491255
[TBL] [Abstract][Full Text] [Related]
20. Bavachin induces the apoptosis of multiple myeloma cell lines by inhibiting the activation of nuclear factor kappa B and signal transducer and activator of transcription 3.
Takeda T; Tsubaki M; Tomonari Y; Kawashima K; Itoh T; Imano M; Satou T; Nishida S
Biomed Pharmacother; 2018 Apr; 100():486-494. PubMed ID: 29477912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
